(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.04%) $0.927
(0.31%) $10.87
(0.07%) $0.793
(-0.31%) $92.29
Live Chart Being Loaded With Signals
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China...
Stats | |
---|---|
Today's Volume | 49.73M |
Average Volume | 3.55M |
Market Cap | 20.16B |
EPS | HKD0 ( 2024-03-26 ) |
Last Dividend | HKD0.342 ( 2023-09-11 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 7.75 |
ATR14 | HKD0.0230 (0.28%) |
Volume Correlation
China Medical System Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
China Medical System Correlation - Currency/Commodity
China Medical System Financials
Annual | 2022 |
Revenue: | HKD9.15B |
Gross Profit: | HKD7.04B (76.89 %) |
EPS: | HKD1.330 |
Q2 | 2023 |
Revenue: | HKD2.31B |
Gross Profit: | HKD1.80B (78.22 %) |
EPS: | HKD0.390 |
Q1 | 2023 |
Revenue: | HKD2.31B |
Gross Profit: | HKD1.80B (78.22 %) |
EPS: | HKD0.390 |
Q4 | 2022 |
Revenue: | HKD2.35B |
Gross Profit: | HKD1.80B (76.55 %) |
EPS: | HKD0.300 |
Financial Reports:
No articles found.
China Medical System Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.337 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.274 (N/A) |
HKD0.342 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.00693 | 2011-03-22 |
Last Dividend | HKD0.342 | 2023-09-11 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 26 | -- |
Total Paid Out | HKD3.99 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.82 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.93 | |
Div. Directional Score | 8.54 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6993.HK | Ex Dividend Knight | 2023-06-20 | Annually | 0 | 0.00% | |
2003.HK | Ex Dividend Knight | 2023-10-17 | Annually | 0 | 0.00% | |
1084.HK | Ex Dividend Junior | 2023-06-06 | Semi-Annually | 0 | 0.00% | |
0168.HK | Ex Dividend Knight | 2023-06-21 | Annually | 0 | 0.00% | |
3658.HK | Ex Dividend Knight | 2023-09-28 | Annually | 0 | 0.00% | |
1651.HK | Ex Dividend Knight | 2023-08-22 | Semi-Annually | 0 | 0.00% | |
0709.HK | Ex Dividend Knight | 2023-09-05 | Semi-Annually | 0 | 0.00% | |
9983.HK | Ex Dividend Junior | 2023-09-18 | Semi-Annually | 0 | 0.00% | |
2199.HK | Ex Dividend Knight | 2023-09-18 | Annually | 0 | 0.00% | |
1223.HK | No Dividend Player | 2023-06-27 | Sporadic | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.363 | 1.500 | 2.74 | 4.11 | [0 - 0.5] |
returnOnAssetsTTM | 0.184 | 1.200 | 3.87 | 4.64 | [0 - 0.3] |
returnOnEquityTTM | 0.221 | 1.500 | 8.65 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.388 | -1.000 | 6.12 | -6.12 | [0 - 1] |
currentRatioTTM | 4.16 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.69 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.01 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0719 | -1.500 | 8.80 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.465 | 2.00 | 9.51 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.457 | 2.00 | 9.27 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0827 | -1.500 | 9.67 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.774 | 1.000 | 0.438 | 0.438 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.387 | 1.000 | 4.26 | 4.26 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.72 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.507 | 0.800 | 9.96 | 7.97 | [0.5 - 2] |
Total Score | 11.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 5.50 | 1.000 | 9.55 | 0 | [1 - 100] |
returnOnEquityTTM | 0.221 | 2.50 | 9.13 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.457 | 2.00 | 9.51 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 8.12 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.465 | 2.00 | 9.51 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.388 | 1.500 | 6.12 | -6.12 | [0 - 1] |
pegRatioTTM | 0.273 | 1.500 | -1.512 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.386 | 1.000 | 2.86 | 0 | [0.1 - 0.5] |
Total Score | 5.93 |
China Medical System
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators